The cost burden of multiple sclerosis in the United States: A systematic review of the literature

Journal of Medical Economics

Volumn 16, Issue 5, 2013, Pages 639-647

  Adelman, Gabriel ^a,b   Rane, Stanley G ^b   Villa, Kathleen F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENENTECH INC   (United States)

Author keywords

Direct costs; Healthcare costs; Indirect costs; Multiple sclerosis; United States

Indexed keywords

PRESCRIPTION DRUG;

ASTHMA; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; EMBASE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; MEDLINE; MENTAL DISEASE; MULTIPLE SCLEROSIS; OSTEOARTHRITIS; PUBLICATION; REVIEW; SYSTEMATIC REVIEW; UNITED STATES;

EID: 84876383332     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.778268     Document Type: Review

References (42)

1. Dutta R, Trapp B. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007;68(22 Suppl 3):S22-31 (Pubitemid 46848608)
2. Kasper LH, Shoemaker J. Multiple sclerosis immunology: the healthy immune system vs the MS immune system. Neurology 2010;74(Suppl 1):S2-8
3. Disanto G. The evidence for a role of B cells in multiple sclerosis. Neurology 2012;78:823-32
4. Multiple sclerosis. PubMed Health. US National Library of Medicine, 2011. www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001747/. Accessed July 31, 2012
5. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85
6. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94 (Pubitemid 26100751)
7. PRISMS. PRISMS-4: long-term efficacy of interferon beta-1a in relapsing MS. Neurology 2001;56:1628-36. Erratum in Neurology 2001;57:1146
8. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability: Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50:701-8
9. Polman C, O'Connor RW, Havrdova E, et al. A randomized placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
10. Ivanova JI, Phillips AL, Bergman RE, et al. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis. J Med Econ 2012; 15:601-9
11. Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009;15:543-55
12. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904
13. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9 (Pubitemid 44563835)
14. Comi G, Martinelli V, Rodegher M, et al; PreCISe Study Group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-11
15. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis. Lancet 2001;357:1576-82 (Pubitemid 32488815)
16. Curkendall SM, Wang C, Johnson BH, et al. Potential health care cost savings associated with early treatment of multiple sclerosis using disease modifying therapy. Clin Ther 2011;14:61-9
17. Brook RA, Rajagopalan K, Kleinman NL, et al. Absenteeism and healthbenefit costs among employees with MS. Curr Med Res Opin 2009;25: 1469-76
18. Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of diseasemodifying therapy for multiple sclerosis: a population-based evaluation. Neurology 2011;77:355-63
19. Rajagopalan K, Brook RA, Beren IA, et al. Comparing costs and absences for multiple sclerosis among US employees: pre- and post-treatment initiation. Curr Med Res Opin 2011;27:179-88
20. Castelli-Haley J, Oleen-Burkey MA, Lage MJ, et al. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. J Med Econ 2010;13:464-71
21. Castelli-Haley J, Oleen-Burkey MA, Lage MJ, et al. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis. Adv Ther 2009;26:552-62
22. Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52 (Pubitemid 46824250)
23. Ivanova JI, Birnbaum HG, Samuels S, et al. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. Pharmacoeconomics 2009;27:681-91
24. Oleen-Burkey M, Castelli-Haley J, Lage MJ, et al. Burden of a multiple sclerosis relapse. Patient 2012;5:57-69
25. Asche CV, Singer ME, Jhaveri M, et al. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm 2010;16:703-12
26. Birnbaum HG, Ivanova JI, Samuels S, et al. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs. Curr Med Res Opin 2009;25:869-77
27. Gilden DM, Kubisiak J, Zbrozek AS. The economic burden of Medicareeligible patients by multiple sclerosis type. Value Health 2011;14:61-9
28. Lad SP, Chapman CH, Vaninetti M, et al. Socioeconomic trends in hospitalization for multiple sclerosis. Neuroepidemiology 2010;35:93-9
29. Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51-61
30. Center for Healthcare Research and Transformation. Health care cost drivers: chronic disease, comorbidity, and health risk factors in the U.S. and Michigan. Issue Brief July 2010. Center for Healthcare Research & Transformation. Ann Arbor, MI. http://www.chrt.org/publications/price-of-care/ issue-brief-2010-08-health-care-cost-drivers/. Accessed November 14, 2012
31. Naci H, Fleurence R, Birt J, et al. Economic burden of multiple sclerosis; A systematic review of the literature. Pharmacoeconomics 2010;28:363-79
32. Sharac J, McCrone P, Sabes-Figuera R. Pharmacoeconomic considerations in the treatment of multiple sclerosis. Drugs 2010;70:1677-91
33. Wundes A, Brown T, Bienen EJ, et al. Contribution of intangible costs to the economic burden of multiple sclerosis. J Med Econ 2010;13:626-32
34. Reese JP, John A, Wienemann G, et al. Economic burden in a German cohort of patients with multiple sclerosis. Eur Neurol 2011;66:311-21
35. Patwardhan MB, Matchar DB, Samsa GP, et al. Cost of multiple sclerosis by level of disability: a review of literature. Multi Scler 2005;11:232-9 (Pubitemid 40403265)
36. Earnshaw SR, Graham J, Castelli-Haley J, et al. Cost-effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy 2009;7:91-108
37. Oleen-Burkey M, Kobelt G, Borgstrom F. Costs and quality of life of patients with relapsing-remitting multiple sclerosis currently on immunomodulatory therapy in the United States. International Committee on Databases in Multiple Sclerosis, 2003; Abstract Hackensack, NJ
38. Kobelt G, Bery J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006;66:1696-702 (Pubitemid 43964625)
39. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308:247-56
40. Von Schaper E, Kresge N. Novartis's $48,000 pill spurs U.S. price increases for older MS treatments. 2011. www.bloomberg.com/news/2011-03-21/ novartis-s-48-000-pill-spurs-u-s-price-increases-for-ms-drugs.html. Accessed July 23, 2012
41. Fox EJ, Rhoades RW. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Curr Opin Neurol 2012;25 (1 Suppl):S11-19
42. US Food and Drug Administration. FDA approves new multiple sclerosis treatment Aubagio. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm319277.htm. Accessed November 2, 2012